EP1483407A4 - Methodes therapeutiques et diagnostiques - Google Patents

Methodes therapeutiques et diagnostiques

Info

Publication number
EP1483407A4
EP1483407A4 EP03709107A EP03709107A EP1483407A4 EP 1483407 A4 EP1483407 A4 EP 1483407A4 EP 03709107 A EP03709107 A EP 03709107A EP 03709107 A EP03709107 A EP 03709107A EP 1483407 A4 EP1483407 A4 EP 1483407A4
Authority
EP
European Patent Office
Prior art keywords
diagnosis
therapy
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP03709107A
Other languages
German (de)
English (en)
Other versions
EP1483407A2 (fr
Inventor
Peter Emtage
Douglas A Dedera
Bryan J Boyle
Jian-Rui Wang
Huang-Tsu Chen
Ching-Yi Wan
Victoria Yamazaki
Vinod Asundi
Chenghua Liu
Y Tom Tang
Radoje T Drmanac
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arca Biopharma Inc
Original Assignee
Nuvelo Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/146,619 external-priority patent/US20030215453A1/en
Priority claimed from US10/218,325 external-priority patent/US7109030B2/en
Priority claimed from US10/302,444 external-priority patent/US20040022786A1/en
Priority claimed from US10/327,413 external-priority patent/US7029677B2/en
Priority claimed from US10/327,491 external-priority patent/US20040023870A1/en
Application filed by Nuvelo Inc filed Critical Nuvelo Inc
Publication of EP1483407A2 publication Critical patent/EP1483407A2/fr
Publication of EP1483407A4 publication Critical patent/EP1483407A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP03709107A 2002-02-14 2003-02-14 Methodes therapeutiques et diagnostiques Ceased EP1483407A4 (fr)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US87137 1987-08-19
US7767602A 2002-02-14 2002-02-14
US77676 2002-02-14
US7808002A 2002-02-15 2002-02-15
US78080 2002-02-15
US8713702A 2002-02-27 2002-02-27
US9298502A 2002-03-06 2002-03-06
US92985 2002-03-06
US10/146,619 US20030215453A1 (en) 2002-05-14 2002-05-14 Methods of therapy and diagnosis using immunotargeting of cells expressing VpreB1 protein
US146619 2002-05-14
US10/218,325 US7109030B2 (en) 2000-03-31 2002-08-12 Methods of therapy and diagnosis using insulin-like growth factor binding protein-like polypeptides and polynucleotides
US218325 2002-08-12
US10/302,444 US20040022786A1 (en) 2000-01-21 2002-11-22 Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
US302444 2002-11-22
US10/327,413 US7029677B2 (en) 2000-01-25 2002-12-19 Methods of therapy and diagnosis using immunotargeting of CD84Hy1-expressing cells
US327491 2002-12-19
US10/327,491 US20040023870A1 (en) 2000-01-21 2002-12-19 Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
US327413 2002-12-19
PCT/US2003/004515 WO2003068935A2 (fr) 2002-02-14 2003-02-14 Méthodes thérapeutiques et diagnostiques

Publications (2)

Publication Number Publication Date
EP1483407A2 EP1483407A2 (fr) 2004-12-08
EP1483407A4 true EP1483407A4 (fr) 2006-11-15

Family

ID=27739558

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03709107A Ceased EP1483407A4 (fr) 2002-02-14 2003-02-14 Methodes therapeutiques et diagnostiques

Country Status (3)

Country Link
EP (1) EP1483407A4 (fr)
CA (1) CA2476555A1 (fr)
WO (1) WO2003068935A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201107118D0 (en) 2011-04-27 2011-06-08 Imp Innovations Ltd Method of diagnosis and prognosis
JP6449777B2 (ja) 2012-12-21 2019-01-09 シアトル ジェネティックス， インコーポレイテッド 抗ｎｔｂ−ａ抗体ならびに関連する組成物および方法
WO2021097538A1 (fr) * 2019-11-22 2021-05-27 The University Of Sydney Formation osseuse
CN113138281B (zh) * 2021-04-28 2024-07-30 首都医科大学附属北京友谊医院 一种原发性噬血细胞综合征的检测装置以及电子设备

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055336A2 (fr) * 2000-01-25 2001-08-02 Hyseq, Inc. Procedes et substances relatifs a des polypeptides de type cd84 et a des polynucleotides
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
WO2001079454A1 (fr) * 2000-04-13 2001-10-25 Smithkline Beecham Corporation Nouveaux composes
EP1223218A1 (fr) * 2000-11-03 2002-07-17 Millennium Pharmaceuticals, Inc. Molecules CD2000 et CD2001 et utilisations de celles-ci

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
WO2001055336A2 (fr) * 2000-01-25 2001-08-02 Hyseq, Inc. Procedes et substances relatifs a des polypeptides de type cd84 et a des polynucleotides
WO2001079454A1 (fr) * 2000-04-13 2001-10-25 Smithkline Beecham Corporation Nouveaux composes
EP1223218A1 (fr) * 2000-11-03 2002-07-17 Millennium Pharmaceuticals, Inc. Molecules CD2000 et CD2001 et utilisations de celles-ci

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BAUER S R ET AL: "VpreB gene expression in hematopoietic malignancies: a lineage- and stage-restricted marker for B-cell precursor leukemias", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 78, no. 6, 15 September 1991 (1991-09-15), pages 1581 - 1588, XP002312599, ISSN: 0006-4971 *
SCHIFF C ET AL: "LAMBDA-LIKE AND V PRE-B GENES EXPRESSION AN EARLY B-LINEAGE MARKER OF HUMAN LEUKEMIAS", BLOOD, vol. 78, no. 6, 1991, pages 1516 - 1525, XP002388533, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
WO2003068935A3 (fr) 2004-06-10
EP1483407A2 (fr) 2004-12-08
WO2003068935A2 (fr) 2003-08-21
CA2476555A1 (fr) 2003-08-21

Similar Documents

Publication Publication Date Title
EP1571968A4 (fr) Compositions et methodes permettant de diagnostiquer et de traiter une tumeur
EP1589933A4 (fr) Compositions et methodes pour le diagnostic et le traitement d'une tumeur
EP1701654A4 (fr) Biocapteur implantable et procedes pour l'utiliser
IL162201A0 (en) New methods for diagnosis and treatment of tumours
EP1551990A4 (fr) Diagnostic et traitement de tumeurs chimio-resistantes
EP1572091A4 (fr) Compositions et methodes de diagnostic et de traitement de tumeurs
EP1553912A4 (fr) Compositions et methodes pour le diagnostic et pour le traitement d'une tumeur
EP1578996A4 (fr) Compositions et methodes pour diagnostiquer et traiter des tumeurs
EP1575571A4 (fr) Compositions et methodes de diagnostic et de traitement d'une tumeur
EP1572741A4 (fr) Agents diagnostiques et therapeutiques
EP1476150A4 (fr) Carboxyfullerenes et procedes d'utilisation de ceux-ci
AU2003287354A8 (en) An intracardiac catheter and method of use
EP1545287A4 (fr) Composes vasoregulateurs et procedes concernant leur utilisation
EP1599226A4 (fr) Procede de diagnostic et de traitement
GB0210741D0 (en) Methods of therapy
AU2003250912A8 (en) Agents and methods for diagnosis and therapy of cancer and cancer risk assessment
EP1483407A4 (fr) Methodes therapeutiques et diagnostiques
AU2003295902A8 (en) Methods of therapy and diagnosis using targeting of cells that express p2y10
EP1567863A4 (fr) Procedes de therapie et de diagnostic
EP1569928A4 (fr) Composes et methodes therapeutiques
GB2404864B (en) Apparatus and method for stimulation of the human body
AU2003235665A8 (en) Diagnostic and therapeutic uses of topors
GB0221712D0 (en) Methods of treatment
EP1583777A4 (fr) Procedes de therapie et de diagnostic utilisant le ciblage de cellules d'expression de ly-9
AU2003201641A8 (en) Treatment and diagnosis of af4-dependant diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040913

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

A4 Supplementary search report drawn up and despatched

Effective date: 20061018

17Q First examination report despatched

Effective date: 20080609

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ARCA BIOPHARMA, INC.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ARCA BIOPHARMA, INC.

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20120928